

IN THE SPECIFICATION:

Please delete the initial paper copy of the Sequence Listing (pages 38-99), and renumber pages 100-102 to 39-41, respectively. Please append the attached substitute paper copy of the Sequence Listing (pages 1-33) to the end of the application.

IN THE CLAIMS:

Please renumber the pages 103-108, containing the claims, to 42-47, respectively.

REMARKS


Applicants have replaced the initial paper copy of the Sequence Listing with a substitute paper copy of the Sequence Listing. Whereas information in the initial paper copy is in the old format, information in the substitute paper copy is in the current format. Both copies of the Sequence Listing contain identical sequences. In the substitute paper copy of the Sequence Listing, the features sections of SEQ ID NOs: 1 and 2 have been corrected for two minor editorial errors, one relating to the location of an intron and the other relating to the source of the sequence. The accompanying computer readable copy of the Sequence Listing contains information in the current format.

Further, pagination of pages containing the specification following the initial paper copy of the Sequence Listing, the Claims and the Abstract have all been appropriately renumbered, accounting for the removal of initial paper copy of the Sequence Listing. The substitute paper copy of the Sequence Listing is fully supported by the specification and initial paper copy of the Sequence Listing. No new matter has been added. Entry of these amendments is respectfully requested.

No fee is believed to be required for this Amendment. Should any fee be required, please charge it to deposit account 19-0134, in the name of Novartis Corporation.

Respectfully submitted,

Date: December 17, 1999

  
\_\_\_\_\_  
George C. Jen  
Attorney for Applicants  
Registration No. 39,239

Novartis Corporation  
P. O. Box 12257  
Research Triangle Park, NC 27709-2257  
Telephone: 919-597-3033